Idenix Pharmaceuticals Rating Reiterated by Morgan Stanley (IDIX)
Idenix Pharmaceuticals (NASDAQ:IDIX)‘s stock had its “equal weight” rating reiterated by stock analysts at Morgan Stanley in a report issued on Tuesday. They currently have a $5.00 price objective on the stock, down from their previous price objective of $24.50. Morgan Stanley’s price target would indicate a potential downside of 78.98% from the company’s current price.
The analysts wrote, “We are increasing our price target to $24.50 in light of Merck’s announced bid for Idenix at $24.50/share. We do not expect other bidders for this company or any data to cause the deal to not happen…We are Equal-weight IDIX and have a $24.50 price target, which is driven by Merck’s announced acquisition price for Idenix. We do not expect other bidders for Idenix.”
Idenix Pharmaceuticals (NASDAQ:IDIX) traded down 0.46% during mid-day trading on Tuesday, hitting $23.68. The stock had a trading volume of 4,144,885 shares. Idenix Pharmaceuticals has a 52-week low of $2.93 and a 52-week high of $24.21. The stock’s 50-day moving average is $6.4 and its 200-day moving average is $6.39. The company’s market cap is $3.572 billion.
Idenix Pharmaceuticals (NASDAQ:IDIX) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.05. On average, analysts predict that Idenix Pharmaceuticals will post $-0.88 earnings per share for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at JMP Securities upgraded shares of Idenix Pharmaceuticals to a “market perform” rating in a research note on Monday. Analysts at Robert W. Baird upgraded shares of Idenix Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Monday. Two analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $4.67.
Idenix Pharmaceuticals, Inc (NASDAQ:IDIX) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.